Highlights from day 3
For the last day of the ELCC 2023 congress in Copenhagen, we asked Dr Anouk Goudsmit (NKI Amsterdam & Institut Jules Bordet, Brussels) to summarize the presentations of the mini oral session 2 on Friday, March 31.
She first discussed the updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3 with cemiplimab in the first-line treatment for locally advanced NSCLC. Then she commented on the TACTI-002, a phase II study with eftilagimod alpha (soluble LAG-3) & pembrolizumab in 2nd line metastatic NSCLC patients resistant to PD-1/PD-L1 inhibitors. Finally, the TRUST-I study was reviewed. During this ELCC, the updated efficacy and safety of taletrectinib in patients with ROS1+ NSCLC was communicated.
With the support of:
